Syntopix Group plc Completes Acquisition and Fundraising
Zeus Capital is pleased to announce that they have advised Syntopix Group plc, on the acquisition of Leeds Skin Centre for Applied Research Limited (“Leeds Skin”) for a total consideration of £900,000 together with a placing to raise £2 million.
Leeds Skin is a private company located in Wetherby, Yorkshire, that runs an independent commercial testing facility specialising in the following:
Human Skin Microbiology;
Living Skin Equivalent tissue culture systems; and
Human Volunteer and Clinical Dermatology Research
Zeus Capital has acted as Nominated Adviser to the Bradford based company which is focused on topical antimicrobial innovations for products in the medicine and consumer healthcare markets since September 2008.
Since its admission to AIM in March 2006 and the subsequent placings in August 2008, March 2010 and May 2011, Syntopix has continued to progress its drug development programme in dermatology and enhance its profile amongst prospective partners. The Group has continued to work on the discovery of compounds and combinations of compounds for use in the treatment of acne, oral hygiene and hair care.